484 results about "Viral Vaccine" patented technology

The invention discloses an adenovirus vector vaccine for preventing SARS-CoV-2 infection. The vaccine comprises a nucleic acid sequence as shown in SEQ ID NO: 1. According to a plurality of embodiments of the invention, the S protein nucleic acid sequence contained in the vaccine is easy to express in human cells, and generation of more S proteins can be induced, so the vaccine is expected to be used as a recombinant virus vaccine for preventing SARS-CoV-2 infection. According to a plurality of embodiments of the invention, the vaccine has good security.

A vector comprising a first DNA sequence which is complementary to at least part of an alphavirus RNA genome and having the complement of complete alphavirus DNA genome replication regions, a second DNA sequence encoding a paramyxovirus protein, particularly a respiratory syncytial virus fusion (RSV F) protein or a RSV F protein fragment that generates antibodies that specifically react with RSV F protein, the first and second DNA sequences being under the transcriptional control of a promoter is described. Such vector may be used to produce an RNA transcript which may be used to immunize a host, including a human host, to protect the host against disease caused by paramyxovirus, particularly respiratory syncytial virus, by administration to the host.

The present invention encompasses influenza vaccines, in particular avian influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing avian influenza antigens, epitopes or immunogens which can be used to protect animals, in particular felids, against avian influenza.

The present invention relates to antigenic and vaccine compositions comprising Norovirus antigens and adjuvants, in particular, mixtures of monovalent VLPs and mixtures of multivalent VLPs, and to a process for the production of both monovalent and multivalent VLPs, the VLPs comprising capsid proteins from one or more Norovirus genogroups.

The invention provides chimeric flavivirus vaccines against West Nile virus and methods of using these vaccines to prevent or treat West Nile virus infection.

Nucleic acid molecules and vector platforms derived from human virus vaccines, for example the alphavirus vaccines, including the TC-83 human vaccine, are disclosed. These vector platforms can provide for expression of a heterologous protein or nucleic acid in animal or human cells. In preferred embodiments, the nucleic acid molecules and vector platforms can be safely used to make and administer vaccines or gene therapies.

We have generated novel molecularly marked FMDV A₂₄LL3D_YR and A₂₄LL3B_PVKV3D_YR vaccine candidates. The mutant viruses contain a deletion of the leader coding region (LL) rendering the virus attenuated in vivo and negative antigenic markers introduced in one or both of the viral non-structural 3D^pol and 3B proteins. The vaccine platform includes unique restriction endonuclease sites for easy swapping of capsid proteins for different FMDV subtypes and serotypes. The mutant viruses produced no signs of FMD and no shedding of virulent virus in cattle. No clinical signs of disease or fever were observed and no transmission to in-contact animals was detected in pigs inoculated with live A₂₄LL3D_YR. Cattle immunized with chemically inactivated vaccine candidates showed an efficacy comparable to a polyvalent commercial FMDV vaccine. These vaccine candidates used in conjunction with a cELISA provide a suitable target for DIVA companion tests.

The invention discloses an establishing method of a bacterial artificial chromosome recombinant duck plague virus rescue system platform and application of the platform. A bacterial artificial chromosome recombinant duck plague virus is obtained by inserting a recombinant duck plague virus transfer vector pUC18/EGFP-TKAB-BAC11 in a TK domain, wherein the recombinant duck plague virus transfer vector contains a TK gene left-right homologous arm, a reporter gene EGFP and a bacterial artificial chromosome core function component. By means of the platform, the in-vitro biologics characteristics of a UL55 gene-deleted strain established through an inside-bacterium two-step RED recombination method and a back mutation strain and parent strain of the UL55 gene-deleted strain are quite close; the functions are not related to positioning of a UL26.5 gene in a cell. The method is beneficial to development of pathogenic mechanism and gene function research of DPV CHv and is beneficial to the duck plague virus prevention and the research and application of recombinant duck plague virus vaccines of other poultry infectious diseases based on the platform; in addition, due to the fact that the recombinant virus carries a TK deletion mark and an EGFP gene, a mark vaccine can be developed to clinically distinguish a wild virus and a recombinant vaccine virus.

The invention provides attenuated Flavivirus vaccines, such as vaccines against Japanese encephalitis virus and West Nile virus, as well as methods of making and using these vaccines.

The present invention relates to a method for purifying recombinant human serum albumin (rHSA) protein. The method comprises the following steps: fermented liquid containing rHSA is processed by a ceramic membrane, supernatant liquid is orderly purified by high salt cation exchange chromatography, hydrophobic layer exchange chromatography and weak anion exchange chromatography, and purified rHSA is obtained. The present invention is characterized in that solution processed by high salt cation exchange chromatography is processed by borate and then filtered by hollow fibers. The rHSA obtained can be used for producing vaccines for humans against viruses with a cell culture method, particularly rabies vaccines.

The present invention relates to multivalent recombinant raccoon poxviruses, containing more than one exogenous gene inserted into either the thymidine kinase gene, the hemagglutinin gene, or a combination thereof. Disclosed is the use of the multivalent recombinant raccoon poxviruses as vaccines to immunize felines against subsequent challenge by feline pathogens. Also disclosed is a method of making a multivalent recombinant raccoon poxvirus by a recombination process involving the construction of an insertion vector into which the exogenous genes are inserted, and flanking the inserted genes are sequences which can recombine into the raccoon poxvirus thymidine kinase gene, or the hemagglutinin gene, or a combination thereof; introducing both the insertion vector containing the exogenous genes, and raccoon poxvirus into susceptible host cells; and selecting the recombinant raccoon poxvirus from the resultant plaques.

The present invention relates to a process for animal, preferably human, diploid anchorage-dependent cell culture, in the absence of exogenous components of primary animal origin, and to a cell culture medium substantially free of exogenous components of primary animal origin suitable for carrying out said process. In particular the invention concerns a cell culture medium which comprises at least one, more preferably several, exogenous animal-free growth factors. The present invention also relates to a process for cultivating animal, preferably human diploid anchorage-dependent cells in a medium according to the invention, involving the use of a trypsin substitute of non-animal origin for passaging cells. The invention further relates to a process for producing viruses, viral vaccines and the like.

The present invention relates to a cell-based method for producing influenza virus vaccines by enriching the population of surface-bound α2,6-sialic acid receptors on a cell surface, such as on a Chinese Hamster Ovary (CHO) cell surface. The host cell therefore presents numerous binding sites to which an influenza virus can bind via its hemagglutinin spike protein and infect the host cell. In contrast to wild-type CHO cells, the surface of the mutated CHO cells of the present invention contains an enriched population of α2,6-sialic acid receptors which makes the inventive CHO cells highly susceptible to viral infection, and therefore safe, effective, and highly efficient cells for rapidly producing influenza vaccines.

What is described is a recombinant vector, such as a virus; for instance, a poxvirus, such as avipox virus, containing foreign DNA from porcine reproductive and respiratory syndrome virus. What are also described are immunological compositions containing the recombinant poxvirus for inducing an immunological response in a host animal to which the immunological composition is administered. Also described are methods of treating or preventing disease caused by porcine reproductive and respiratory syndrome virus by administering the immunological compositions of the invention to an animal in need of treatment or susceptible to infection by porcine reproductive and respiratory syndrome virus.

The present invention relates to recombinant anti-Nipah virus vaccines and the administration of such vaccines to animals, advantageously pigs. Advantageously, the anti-Nipah virus vaccine may comprise a recombinant avipox virus containing a Nipah virus glycoprotein gene. The invention encompasses methods of vaccinating animals, advantageously pigs, by administration of anti-Nipah virus vaccines that may comprise a recombinant avipox virus that may contain a Nipah virus glycoprotein gene.

The invention relates to preparation of a vaccine for hand-foot-and-mouth disease viruses and an application method thereof, belonging to a novel vaccine for preventing infectious diseases. The vaccine of the invention mainly comprises the components of high-purified inactivated human enteropathogenic virus 71 (EV 71) and an aluminum adjuvant. The vaccine, which is prepared according to the method of the invention, has excellent immunogenicity, and after immunity, organisms can selectively generate a high titer serum neutralization antibody, thereby preventing infectious diseases caused by the human EV 71.

DNA and protein constructs useful in producing vaccines against human cytomegalovirus contain optionally N-end modified and N-terminal ubiquitinated human cytomegalovirus antigenic proteins, including pp65, pp150, IE1, gB and antigenic fragments thereof. Vaccine viruses, in particular poxviruses such as vaccinia and Modified Vaccinia Ankara, that express the constructs may be used as vaccines to augment the immune response to human cytomegalovirus, both prophylatically and in patients already carrying human cytomegalovirus, as well as to create and expand cytomegalovirus-reactive T cells for transfer of adoptive immunity.

The invention discloses a construction method of a mandarin fish brain cell system. Aiming at the characteristic of mandarin fish brain cells, the primary cell culture is carried out by separating the brain cells through a serum-contained collagenase digestion method, so that the mandarin fish brain cell system is constructed successfully. Thus, a great quantity of mandarin fish brain source cells can be provided; and the good growth status of sub-culture cells can be maintained. The construction method is strong in repeatability and brings convenience for researching fish virus infection paths and fish virus infection mechanisms, developing viral vaccines and the like.

The present invention is directed to genetically engineered, membrane-enveloped viruses with deletion mutations in the protein transmembrane domains. Also provided are viral vaccines based on the engineered viruses, methods of producing and using such vaccines.

The present application describes improved an immunogenic compositions of virus vaccines wherein the virus vaccines comprise adjuvants selected from the group consisting of MCP-1, Haemophilus sonmus fractions, carbomer and combinations thereof. Methods and compositions using such improved compositions are described.

The invention discloses a preparation method of a recombinant pseudorabies virus for expressing reverse neural circuit tracing of green fluorescin with high sensitivity, and application, including (1) the preparation of the recombinant pseudorabies virus for expressing green fluorescin with high sensitivity; (2) the application to marking of a neural circuit. The recombinant pseudorabies virus for expressing the green fluorescin with high sensitivity is successfully prepared by using a platform. The recombinant pseudorabies virus for expressing reverse neural circuit tracing of green fluorescin with high sensitivity is successfully obtained. Wide application value is realized in aspects of neural circuit marking, medicine screening platform building, medicine inhibition virus action mechanism, viral vaccine and diagnostic reagent invention and development, animal model building, virus replication, pathogenic mechanism analysis and the like.

The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.